Botanix Pharmaceuticals
Update in progressBOT.AX (ASX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Botanix Pharmaceuticals Limited is a commercial dermatology company serving Australia and the United States. Its lead product, Sofdra (sofpironium) topical gel, is a prescription anticholinergic for underarm sweating in adults and children aged 9 and up. Its pipeline includes BTX 1503 (transdermal gel for serious acne), BTX 1801 (S. aureus and MRSA), BTX 1702 (papulopustular rosacea), and BTX 1204A (atopic dermatitis). Incorporated 1984; based in West Perth, Australia.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.10
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!